Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Donepezil · 1 trial · 1 indication
Change in Area between treatment arms (compared to baseline), measured during the electrical hyperalgesia model using 26 Milli Neuton(mN) von Frey filament
Change in Area between treatment arms (compared to baseline), measured during the electrical hyperalgesia model using a cotton bud
| Arm | Type | Description |
|---|---|---|
| Gabapentin lower dose alone | EXPERIMENTAL | low dose |
| Gabapentin higher dose alone | ACTIVE_COMPARATOR | higher dose |
| Gabapentin in combination with donepezil | EXPERIMENTAL | Gabapentin lower dose and donepezil |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Gabapentin lower dose | DRUG | Repeat, oral dose |
| Donepezil | DRUG | Repeat, oral dose |
| Placebo (Dop) | OTHER | Placebo to donepezil, Repeat, oral dose |
| Placebo (Gaba) | OTHER | Placebo to gabapentin, Repeat, oral dose |
| Gabapentin higher dose | DRUG | Repeat, oral dose |
Inclusion Criteria: 1. Male between 18 and 55 years of age inclusive, at the time of signing the informed consent. 2. Body weight ≥ 50 Kilogram (kg) and BMI within the range 18.5-29.9 Killogram per square meter (kg/m2) (inclusive). 3. Healthy as determined by a responsible and experienced physician...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE2 | LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA |
| Dogwood Therapeutics Inc | DWTX | 1 | PHASE2 | Halneuron |
| Sangamo Therapeutics, Inc. | SGMO | 1 | PHASE1 | ST-503 |
| Boston Scientific Corporation | BSX | 1 | N/A | Undisclosed |
| Collegium Pharmaceutical, Inc. | COLL | 1 | N/A | Undisclosed |
Donepezil is being studied for the treatment of neuropathic pain. It is a small molecule in Phase 1 clinical development. In a completed early-stage trial, it was evaluated in combination with gabapentin on experimental human pain models in healthy volunteers.
Donepezil is being developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical research on this drug for neuropathic pain.
Donepezil is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug is not yet approved for any use. It remains investigational and is being studied for its potential in treating neuropathic pain.
Donepezil has one completed clinical trial, NCT01485185, titled "Gabapentin and Donepezil Combination on Experimental Human Pain Models." This Phase 1 study enrolled 48 male participants aged 18 years and older in the United Kingdom and was placebo-controlled and double-blind.
The specific molecular target of Donepezil is not disclosed in the available clinical trial information. The drug is being investigated for its effects on neuropathic pain, but its mechanism of action has not been detailed in the public trial data.